Dephosphorylation-induced EZH2 activation mediated RECK downregulation by ERK1/2 signaling

被引:8
作者
Ning, Shilong [1 ]
Ma, Xiao [2 ]
机构
[1] Jinhua Municipal Cent Hosp, Dept Clin Nutr, Jinhua 321000, Zhejiang, Peoples R China
[2] Jinhua Municipal Cent Hosp, Dept Hlth Educ & Adm, Jinhua, Zhejiang, Peoples R China
关键词
ERK1; 2; EZH2; H3K27me3; RECK; CANCER; INHIBITION; THERAPY; CELLS;
D O I
10.1002/jcp.28540
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) gene, a widely known cancer inhibitor, could effectively suppress cancer metastasis and angiogenesis. Downregulation or loss of RECK expression frequently occurs during cancer progression. However, the mechanism underlying RECK dysregulation has not been fully elucidated. Herein, we reportedfor the first time that enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, could epigenetically attenuate RECK expression via catalyzingH3K27 trimethylation (H3K27me3) within the RECK promoter. Furthermore, we also proved, for the first time, the involvement of EZH2 in the inhibition of RECK byextracellular signal-related kinases (ERK)-1/2 signaling. Next, we revealed that the modulation of the enzymic activity of EZH2 resulting from posttranslational phosphorylation at the serine-21 site was responsible for the increased enrichment of H3K27me3 at the RECK promoter region by ERK1/2 signaling. Collectively, the results of our study shed more light on the mechanisms responsible for the dysregulation of RECK by the ERK1/2 pathway.
引用
收藏
页码:19010 / 19018
页数:9
相关论文
共 26 条
  • [1] Alexius-Lindgren M, 2014, ANTICANCER RES, V34, P3867
  • [2] Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis
    Au, Sandy Leung-Kuen
    Wong, Carmen Chak-Lui
    Lee, Joyce Man-Fong
    Fan, Dorothy Ngo-Yin
    Tsang, Felice Hoching
    Ng, Irene Oi-Lin
    Wong, Chun-Ming
    [J]. HEPATOLOGY, 2012, 56 (02) : 622 - 631
  • [3] MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
    Caunt, Christopher J.
    Sale, Matthew J.
    Smith, Paul D.
    Cook, Simon J.
    [J]. NATURE REVIEWS CANCER, 2015, 15 (10) : 577 - 592
  • [4] Akt-mediated phsophorylationof EZH2 suppresses methylation of lysine 27 in histone H3
    Cha, TL
    Zhou, BHP
    Xia, WY
    Wu, YD
    Yang, CC
    Chen, CT
    Ping, B
    Otte, AP
    Hung, MC
    [J]. SCIENCE, 2005, 310 (5746) : 306 - 310
  • [5] EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
    Chang, Chun-Ju
    Yang, Jer-Yen
    Xia, Weiya
    Chen, Chun-Te
    Xie, Xiaoming
    Chao, Chi-Hong
    Woodward, Wendy A.
    Hsu, Jung-Mao
    Hortobagyi, Gabriel N.
    Hung, Mien-Chie
    [J]. CANCER CELL, 2011, 19 (01) : 86 - 100
  • [6] Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-κB signaling pathway
    Che, Qi
    Liu, Bin-Ya
    Wang, Fang-Yuan
    He, Yin-Yan
    Lu, Wen
    Liao, Yun
    Gu, Wei
    Wan, Xiao-Ping
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 446 (01) : 167 - 172
  • [7] JAK2 regulates mismatch repair protein-mediated epigenetic alterations in response to oxidative damage
    Ding, Ning
    Miller, Sam A.
    Savant, Sudha S.
    O'Hagan, Heather M.
    [J]. ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2019, 60 (04) : 308 - 319
  • [8] Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential
    Gan, Lu
    Yang, Yanan
    Li, Qian
    Feng, Yi
    Liu, Tianshu
    Guo, Weijian
    [J]. BIOMARKER RESEARCH, 2018, 6
  • [9] (Pro)renin receptor activation increases profibrotic markers and fibroblast-like phenotype through MAPK-dependent ROS formation in mouse renal collecting duct cells
    Gonzalez, Alexis A.
    Zamora, Leonardo
    Reyes-Martinez, Cristian
    Salinas-Parra, Nicolas
    Roldan, Nicole
    Cuevas, Catherina A.
    Figueroa, Stefanny
    Gonzalez-Vergara, Alex
    Prieto, Minolfa C.
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2017, 44 (11): : 1134 - 1144
  • [10] The promise of epigenetic therapy: reprogramming the cancer epigenome
    Kelly, Andrew D.
    Issa, Jean-Pierre J.
    [J]. CURRENT OPINION IN GENETICS & DEVELOPMENT, 2017, 42 : 68 - 77